NASDAQ:AVRO AVROBIO (AVRO) Stock Price, News & Analysis → They said crypto was dead. It went up 100X. (From InvestorPlace) (Ad) Free AVRO Stock Alerts $1.29 -0.01 (-0.77%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$1.27▼$1.3050-Day Range$1.15▼$1.4552-Week Range$0.57▼$1.70Volume301,725 shsAverage Volume331,753 shsMarket Capitalization$57.50 millionP/E RatioN/ADividend YieldN/APrice Target$3.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get AVROBIO alerts: Email Address AVROBIO MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside158.4% Upside$3.33 Price TargetShort InterestHealthy0.32% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom $0.58 to ($0.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.44 out of 5 starsMedical Sector614th out of 947 stocksBiological Products, Except Diagnostic Industry111th out of 159 stocks 3.2 Analyst's Opinion Consensus RatingAVROBIO has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.33, AVROBIO has a forecasted upside of 158.4% from its current price of $1.29.Amount of Analyst CoverageAVROBIO has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.32% of the float of AVROBIO has been sold short.Short Interest Ratio / Days to CoverAVROBIO has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AVROBIO has recently decreased by 4.19%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAVROBIO does not currently pay a dividend.Dividend GrowthAVROBIO does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVRO. Previous Next 3.4 News and Social Media Coverage News SentimentAVROBIO has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for AVROBIO this week, compared to 1 article on an average week.Search Interest3 people have searched for AVRO on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows2 people have added AVROBIO to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AVROBIO insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.20% of the stock of AVROBIO is held by insiders.Percentage Held by Institutions59.95% of the stock of AVROBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AVROBIO are expected to decrease in the coming year, from $0.58 to ($0.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AVROBIO is -12.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AVROBIO is -12.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAVROBIO has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About AVROBIO Stock (NASDAQ:AVRO)AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1, as well as to treat Gaucher disease type 3; AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease; AVR-RD-04, which is in phase 1/2 clinical trial for the treatment of cystinosis; and AVR-RD-05 that is in preclinical stage for the treatment of Hunter syndrome. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More AVRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVRO Stock News HeadlinesFebruary 23, 2024 | ca.finance.yahoo.comAVRO Apr 2024 2.500 callFebruary 18, 2024 | finance.yahoo.comAVRO May 2024 2.500 callMarch 19, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:February 14, 2024 | businesswire.comAVROBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVROJanuary 31, 2024 | stockhouse.comShareholder Alert: Ademi LLP investigates whether AVROBIO, Inc. has obtained a Fair Price in its transaction with TectonicJanuary 31, 2024 | bizjournals.comFive things: Vertex's new drug, a reverse merger, and how are you doing?January 31, 2024 | msn.comAvrobio Inc Announces Executive Team Changes and AppointmentsJanuary 30, 2024 | bizjournals.comAvrobio to take Watertown biotech public via reverse mergerMarch 19, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… January 30, 2024 | stockhouse.comSHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AVRO, CALB, BCALJanuary 30, 2024 | msn.comAvrobio to buy 100% equity interests of Tectonic TherapeuticJanuary 30, 2024 | marketwatch.comAvrobio Shares Dive 17% After Tectonic Therapeutic DealJanuary 30, 2024 | finance.yahoo.comAVROBIO and Tectonic Therapeutic Announce MergerDecember 20, 2023 | benzinga.comAvrobio Stock (NASDAQ:AVRO), Analyst Ratings, Price Targets, PredictionsDecember 19, 2023 | msn.comMizuho Downgrades AVROBIO (AVRO)December 19, 2023 | benzinga.comAvrobio Stock (NASDAQ:AVRO) Dividends: History, Yield and DatesDecember 18, 2023 | realmoney.thestreet.comAvrobio just downgraded at Mizuho, here's whyNovember 14, 2023 | morningstar.comAvrobio Inc AVRONovember 14, 2023 | markets.businessinsider.comPotential Growth and Strategic Alternatives: Reasons Behind Zhu’s Buy Rating for AvrobioNovember 8, 2023 | finance.yahoo.comIs AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year?October 6, 2023 | finance.yahoo.comHas AVROBIO (AVRO) Outpaced Other Medical Stocks This Year?October 5, 2023 | msn.comAvroBio (AVRO) Price Target Increased by 12.82% to 3.74September 25, 2023 | ca.finance.yahoo.comAVROBIO, Inc. (AVRO)September 11, 2023 | benzinga.comSolu Therapeutics Appoints Philip Vickers, Ph.D., as President and Chief Executive OfficerAugust 12, 2023 | msn.comAvrobio: Net-Net Biotech Pursuing Strategic AlternativesAugust 11, 2023 | markets.businessinsider.comAvrobio (AVRO) Gets a Buy from BarclaysAugust 7, 2023 | finance.yahoo.comArbor Biotechnologies Appoints Deanna M. Petersen as Chief Business OfficerSee More Headlines Receive AVRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today3/19/2024Next Earnings (Estimated)3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:AVRO CUSIPN/A CIK1681087 Webwww.avrobio.com Phone(617) 914-8420FaxN/AEmployees78Year FoundedN/APrice Target and Rating Average Stock Price Target$3.33 High Stock Price Target$6.00 Low Stock Price Target$2.00 Potential Upside/Downside+158.4%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.10) Trailing P/E RatioN/A Forward P/E Ratio2.22 P/E GrowthN/ANet Income$-105,890,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-97.36% Return on Assets-79.74% Debt Debt-to-Equity RatioN/A Current Ratio14.44 Quick Ratio14.44 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.72 per share Price / Book0.75Miscellaneous Outstanding Shares44,570,000Free Float40,473,000Market Cap$57.50 million OptionableOptionable Beta1.24 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Erik John Ostrowski M.B.A. (Age 52)President, Interim Chief Executive Officer, CFO & Treasurer Comp: $947.29kMs. Azadeh Golipour Ph.D. (Age 45)Chief Technology Officer Comp: $728.21kMr. Jeffrey Medin Ph.D.Scientific FounderMr. Steven N. Avruch J.D. (Age 63)Chief Legal Officer & Secretary Comp: $506.68kMr. Scott GottesmanVice President of Human ResourceMr. Andreas KouriSenior Vice President of Global Supply Chain & External ManufacturingDr. Essra Ridha FFPM (Age 43)M.D., Chief Medical Officer Ms. Kirsten DupuisChief of StaffMore ExecutivesKey CompetitorsJATT AcquisitionNYSE:JATTCortexymeNASDAQ:CRTXCurisNASDAQ:CRISCognition TherapeuticsNASDAQ:CGTXCASI PharmaceuticalsNASDAQ:CASIView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 27,000 shares on 3/11/2024Ownership: 3.594%Newtyn Management LLCBought 734,175 shares on 2/15/2024Ownership: 6.135%Vanguard Group Inc.Bought 27,000 shares on 2/15/2024Ownership: 3.594%Bridgeway Capital Management LLCBought 92,587 shares on 2/15/2024Ownership: 0.538%ADAR1 Capital Management LLCBought 50,147 shares on 2/14/2024Ownership: 0.113%View All Institutional Transactions AVRO Stock Analysis - Frequently Asked Questions Should I buy or sell AVROBIO stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AVROBIO in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" AVRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AVRO, but not buy additional shares or sell existing shares. View AVRO analyst ratings or view top-rated stocks. What is AVROBIO's stock price target for 2024? 3 Wall Street research analysts have issued 12 month price targets for AVROBIO's shares. Their AVRO share price targets range from $2.00 to $6.00. On average, they expect the company's stock price to reach $3.33 in the next twelve months. This suggests a possible upside of 158.4% from the stock's current price. View analysts price targets for AVRO or view top-rated stocks among Wall Street analysts. How have AVRO shares performed in 2024? AVROBIO's stock was trading at $1.36 at the start of the year. Since then, AVRO shares have decreased by 5.1% and is now trading at $1.29. View the best growth stocks for 2024 here. When is AVROBIO's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our AVRO earnings forecast. How were AVROBIO's earnings last quarter? AVROBIO, Inc. (NASDAQ:AVRO) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.75) earnings per share for the quarter, meeting the consensus estimate of ($0.75). What other stocks do shareholders of AVROBIO own? Based on aggregate information from My MarketBeat watchlists, some companies that other AVROBIO investors own include Sorrento Therapeutics (SRNE), ImmunoGen (imgn), Aduro Biotech (ADRO), Aldeyra Therapeutics (ALDX), Amarin (AMRN), Biohaven (BHVN), Nabriva Therapeutics (NBRV), Selecta Biosciences (SELB), VBI Vaccines (vbiv) and Arbutus Biopharma (ABUS). When did AVROBIO IPO? (AVRO) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush Securities was co-manager. Who are AVROBIO's major shareholders? AVROBIO's stock is owned by many different retail and institutional investors. Top institutional investors include Newtyn Management LLC (6.13%), Vanguard Group Inc. (3.59%), Vanguard Group Inc. (3.59%), Vazirani Asset Management LLC (1.46%), FNY Investment Advisers LLC (0.90%) and GABELLI & Co INVESTMENT ADVISERS INC. (0.79%). View institutional ownership trends. How do I buy shares of AVROBIO? Shares of AVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AVRO) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AVROBIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.